Capricor Therapeutics is trading at $6.93, up 11.24%; no clearly confirmed October 29 catalyst explains the rise. - A report covered final HOPE-2 results, including a reported 71% reduction in upper-limb function decline versus placebo, but did not establish that the news drove the move. - Major U.S. indices were lower, so broad-market strength does not explain the gain. - Recent company data and the November 22 FDA decision are background, not confirmed causes of this session’s move.